IN2015DN02868A - - Google Patents
Download PDFInfo
- Publication number
- IN2015DN02868A IN2015DN02868A IN2868DEN2015A IN2015DN02868A IN 2015DN02868 A IN2015DN02868 A IN 2015DN02868A IN 2868DEN2015 A IN2868DEN2015 A IN 2868DEN2015A IN 2015DN02868 A IN2015DN02868 A IN 2015DN02868A
- Authority
- IN
- India
- Prior art keywords
- methods
- impaired glucose
- glucose homeostasis
- cell dysfunction
- cmpf
- Prior art date
Links
- WMCQWXZMVIETAO-UHFFFAOYSA-N 2-(2-carboxyethyl)-4-methyl-5-propylfuran-3-carboxylic acid Chemical compound CCCC=1OC(CCC(O)=O)=C(C(O)=O)C=1C WMCQWXZMVIETAO-UHFFFAOYSA-N 0.000 abstract 4
- 230000014101 glucose homeostasis Effects 0.000 abstract 4
- 230000001771 impaired effect Effects 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 4
- 230000003820 β-cell dysfunction Effects 0.000 abstract 4
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/507—Pancreatic cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
- G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
- G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
- G01N2030/8822—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261703867P | 2012-09-21 | 2012-09-21 | |
US201361787718P | 2013-03-15 | 2013-03-15 | |
PCT/CA2013/000798 WO2014043793A1 (en) | 2012-09-21 | 2013-09-20 | Cmpf as a biomarker for diabetes and associated methods |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015DN02868A true IN2015DN02868A (enrdf_load_stackoverflow) | 2015-09-11 |
Family
ID=50340483
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2868DEN2015 IN2015DN02868A (enrdf_load_stackoverflow) | 2012-09-21 | 2013-09-20 |
Country Status (8)
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015006160A2 (en) | 2013-07-09 | 2015-01-15 | Stemina Biomarker Discovery, Inc. | Biomarkers of autism spectrum disorder |
US20180028100A1 (en) * | 2015-02-11 | 2018-02-01 | Siemens Aktiengesellschaft | System and non-invasive method for examining at least parts of blood fractions, and use of the system |
CN104678016B (zh) * | 2015-02-11 | 2017-05-03 | 浙江中烟工业有限责任公司 | 一种采用高效液相色谱测定苯并芘在吸烟后大鼠肺部沉积量的方法 |
WO2016145532A1 (en) * | 2015-03-16 | 2016-09-22 | The Governing Council Of The University Of Toronto | Cmpf for the treatment or prevention of hepatic steatosis |
WO2018042072A1 (en) * | 2016-09-02 | 2018-03-08 | Afekta Technologies Oy | Furan fatty acid biomarkers of nutritional status |
CN109765360B (zh) * | 2018-12-12 | 2020-01-21 | 杭州博谱医药科技有限公司 | Cmpf均相酶免疫检测试剂盒、制备方法及检测方法 |
CN110007092A (zh) * | 2019-04-08 | 2019-07-12 | 杭州博谱医药科技有限公司 | 一种胶乳微球-蛋白-cmpf偶联物及其制备方法以及测定血清中cmpf含量的试剂盒 |
CN110187123B (zh) * | 2019-05-06 | 2022-07-22 | 天津医科大学总医院 | 一种糖尿病早期诊断生物标志物及其应用 |
CN114924011B (zh) * | 2022-06-30 | 2023-08-25 | 重庆大学附属肿瘤医院 | 高效液相色谱串联质谱法检测血浆中cmpf含量的方法 |
EP4385508A1 (en) * | 2022-12-16 | 2024-06-19 | Centre de Coopération Internationale en Recherche Agronomique pour le Développement (CIRAD) | Furan fatty acids for enhancing muscle mass |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2227689B1 (en) * | 2007-11-02 | 2012-12-26 | Metabolon, Inc. | Biomarkers for fatty liver disease and methods using the same |
WO2010045180A1 (en) | 2008-10-13 | 2010-04-22 | Metabolon, Inc. | Biomarkers for inflammatory bowel disease and methods using the same |
WO2010045474A2 (en) * | 2008-10-16 | 2010-04-22 | Fresenius Medical Care Holdings, Inc. | Method of removing protein-bound deleterious substances during extracorporeal renal replacement treatment |
US8980548B2 (en) | 2010-05-19 | 2015-03-17 | Metabolon, Inc. | Methods and reagents for metabolomics and histology in a biological sample and a kit for the same |
US20130217647A1 (en) | 2010-07-28 | 2013-08-22 | Metabolon, Inc. | Biomarkers for Prostate Cancer and Methods Using the Same |
US20140303228A1 (en) | 2011-10-18 | 2014-10-09 | Metabolon, Inc. | Biomarkers for Amyotrophic Lateral Sclerosis and Methods Using the Same |
JP2015505965A (ja) * | 2011-12-09 | 2015-02-26 | メタボロン,インコーポレイテッド | 腎癌のバイオマーカーおよびそれを用いる方法 |
-
2013
- 2013-09-20 IN IN2868DEN2015 patent/IN2015DN02868A/en unknown
- 2013-09-20 US US14/429,977 patent/US9726659B2/en not_active Expired - Fee Related
- 2013-09-20 WO PCT/CA2013/000798 patent/WO2014043793A1/en active Application Filing
- 2013-09-20 CA CA2885416A patent/CA2885416A1/en not_active Abandoned
- 2013-09-20 MX MX2015003642A patent/MX2015003642A/es unknown
- 2013-09-20 CN CN201380060932.9A patent/CN104822378A/zh active Pending
- 2013-09-20 BR BR112015006284A patent/BR112015006284A2/pt not_active IP Right Cessation
- 2013-09-20 EP EP13839563.7A patent/EP2897614A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
MX2015003642A (es) | 2016-07-11 |
US20150247839A1 (en) | 2015-09-03 |
EP2897614A1 (en) | 2015-07-29 |
BR112015006284A2 (pt) | 2017-07-04 |
US9726659B2 (en) | 2017-08-08 |
CA2885416A1 (en) | 2014-03-27 |
EP2897614A4 (en) | 2016-04-13 |
CN104822378A (zh) | 2015-08-05 |
WO2014043793A1 (en) | 2014-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2015DN02868A (enrdf_load_stackoverflow) | ||
MX382244B (es) | Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales | |
WO2011047033A3 (en) | Biomarker for identification of melanoma tumor cells | |
WO2016094904A8 (en) | Methods of measuring erbb signaling pathway activity to diagnose and treat cancer patients | |
EA201590024A1 (ru) | Способы определения заболеваний или состояний с применением циркулирующих болезненных клеток | |
WO2012083004A3 (en) | Blood-borne mirnas as surrogate markers of drug efficacy for cardiac conditions | |
EA201391187A1 (ru) | Способ диагностики злокачественной опухоли и набор для диагностики путем измерения активности nk-клеток | |
EA201500080A1 (ru) | Способ in vitro диагностирования и мониторинга рака | |
BR112013003160A2 (pt) | tratamento de diabetes com células precursoras endócrinas pancráticas | |
IN2014MN02101A (enrdf_load_stackoverflow) | ||
MX2020006720A (es) | Beta-caseina a2 y niveles de glucosa en sangre. | |
IN2014DN08537A (enrdf_load_stackoverflow) | ||
WO2011103330A3 (en) | Novel phosphorylation of cardiac troponin i as a monitor for cardiac injury | |
MX2015008436A (es) | Composiciones para permeabilizar celulas sanguineos fijos y sus usos. | |
BR112014009310A2 (pt) | métodos de avaliação de riscos de lmp e aparelhos relacionados | |
WO2014047442A3 (en) | Biomarkers for assessing treatment of sialic acid deficiency diseases and conditions | |
WO2010138610A3 (en) | Novel desmin phosphorylation sites useful in diagnosis and intervention of cardiac disease | |
WO2012074882A3 (en) | Phagocytic activity as a marker of synucleinopathic disease | |
AU2012313353A8 (en) | Screening method | |
WO2012145399A3 (en) | Methods of diagnosing cancer in a patient | |
WO2012129395A3 (en) | Diagnosis and treatment of prostate cancer | |
WO2012024302A3 (en) | Biomarkers of cancer | |
EA201001297A1 (ru) | Способ диагностики меланомы человека на основании определения уровня экспрессии гена phf10, диагностический набор | |
RU2009145339A (ru) | Способ оценки степени тяжести нарушения агрегации эритроцитов | |
UA45411U (ru) | Способ прогнозирования тяжести течения лептоспироза |